DMAC Valuation

DiaMedica Therapeutics Inc

Add to Watchlist

Advanced Chart

4.600

+0.06(1.322%)1D

Overview
Forecast
Valuation
Earnings

DMAC Relative Valuation

DMAC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DMAC is overvalued; if below, it's undervalued.

Historical Valuation

DiaMedica Therapeutics Inc (DMAC) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.00. The fair price of DiaMedica Therapeutics Inc (DMAC) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：4.60

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

5.73

P/B

Median3y

2.61

Median5y

3.11

-12.61

FCF Yield

Median3y

-18.65

Median5y

-16.13

Competitors Valuation Multiple

The average P/S ratio for DMAC's competitors is 0.93, providing a benchmark for relative valuation. DiaMedica Therapeutics Inc Corp (DMAC) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

DMAC.O

DiaMedica Therapeutics Inc

Loss

Average P/S: 0.93

197.26M